In the pharmaceutical sector, choosing suppliers is essential to guarantee the effectiveness, dependability, and quality of the supply chain. Pharmaceutical firms face a vital problem in strategically selecting their suppliers due to strict regulatory constraints, increasing demands for innovation, and an emphasis on cost-effectiveness. Securing a strong supply chain, reducing risks, and maintaining the pharmaceutical industry's dedication to providing safe and effective drugs all depend on efficient supplier selection procedures. This changing environment emphasizes how important it is for the pharmaceutical industry to choose suppliers carefully. In this chapter, the fuzzy Analytical Hierarchy Process (AHP) is employed to establish the normalized weight attributes. Subsequently, the fuzzy Multi-Attributive Border Approximation Area Comparison (MABAC) approach is utilized for pharmaceutical supplier selection. The comprehensive supplier assessment involves evaluating six criteria, each with five alternatives. A normalization process is applied to derive the weighted normalized fuzzy decision matrix. Beneficial and non-beneficial criteria are computed for each alternative, leading to the determination of an overall performance index. Next, based on the final table's descending total performance index values, the alternatives are ranked from best to worst. According to the study's outcomes, when choosing a pharmaceutical supplier, the alternative with the greatest overall performance index is the best option.